Geftinib

Journal of Cancer Research and Therapeutics

Volumn 6, Issue 3, 2010, Pages 249-254

  Gupta, Ajay ^a   Raina, Vinod ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Geftinib; lung cancer; tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CLARITHROMYCIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; GEMCITABINE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; NAVELBINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PLATINUM DERIVATIVE; RIFAMPICIN;

ACNE; ADD ON THERAPY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEVER; GENE DOSAGE; GENE MUTATION; GENOTYPE; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; LAZARUS THEORY OF STRESS AND COPING; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; MUTATION; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 78650080843     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.73330     Document Type: Review

References (48)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
2. Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. none Int J Biol Markers 2007;22:S24-39.
3. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-7.
4. DiGennaro E, Marcella B, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, et al. Growth inhibition of tumor cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors. Clin Cancer Res 1999;5:3753S
5. Baselga J, Averbuch SD. ZD1839 (Iressa) as an anticancer agent. Drugs 2000;60:33-40.
6. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J. Selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 2002;20:3815-25.
7. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: Gefitinib. Oncologist 2003;8:303-6.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
9. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
10. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
11. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
12. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al. Lung Cancer with epidermal growth factor receptor Exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14:4877-82.
13. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
14. Bailey LR, Kris M, Wolf M. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving geftinib monotherapy for pretreated advanced non-small lung cancer. IDEAL 1 and IDEAL 2. Proc Am Assoc Cancer Res 2003;44:1362.
15. Pan ZK, Zhang L, Wang X, Li N, Xu F, Chang JH, et al. Epidermal growth factor mutation in Chinese patients with non-small cell lung cancer. Ai Zheng 2005;24:919-23.
16. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemo refractory lung adenocarcinomas. Clin Cancer Res 2005;11:5878-85.
17. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J. Geftinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer. Lancet 2005;366:1527-37.
18. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46.
19. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-58.
20. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42.
21. Lim ST, Wong EH, Chuah KL, Leong SS, Lim WT, Tay MH, et al. Gefitinib is more effective in never-smokers with non-small-cell lung cancer: Experience among Asian patients. Br J Cancer 2005;93:23-8.
22. Ho C, Murray N, Laskin J, Melosky B, Anderson H, Bebb G. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005;49:225-31.
23. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-8.
24. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. J Thorac Oncol 2006;1:545-50.
25. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: A prospective phase II study. J Chemother 2005;7:679-84.
26. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52.
27. Parikh P, Chang AY, Nag S, Digumarti R, Bhattacharyya GS, Doval DC, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol 2008;3:380-5.
28. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005;6:1081-6.
29. Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K; SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-9.
30. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL,none et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-18.
31. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
32. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
33. Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM. Geftinib as front line treatment in Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2006;54:193-9.
34. Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, et al. Survival outcome and predictors of Geftinib antitumor activity in East Asian Chemo-naïve patients with advanced non-small cell lung cancer. Cancer 2006;107:1873-82.
35. Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, Thomas M, et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: A Minnie Pearl Cancer Research Network Phase II Trial. Clin Lung Cancer 2005;7:127-32.
36. Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
37. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 2008;26:4253-60.
38. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004.
39. Tamura K, Okamoto I, Kashii T et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-14.
40. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9.
41. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21.
42. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6.
43. Morita S, Hirashima T, Hagiwara K, Hida T, Sunaga N, Sugio K, et al. I-CAMP Study Group. Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP). J Clin Oncol 2008;26:15S.
44. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6.
45. Pallis AG, Christofillakis CH, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, et al. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multi-center phase II trial. Lung Cancer 2007;55:101-7.
46. Hida T, Okamoto I, Kashii T, Satouchi M, Ichinose Y, Katakami N, et al. Randomised phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol 2008;26:LBA8012.
47. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005;23:175-83.
48. Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006;6:323-31.